BChE-IN-13 (Compound 17c) is an orally active, potent, and selective inhibitor of Butyrylcholinesterase (BChE), exhibiting IC50 values of 0.22 μM and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 enhances memory and cognitive impairments, making it valuable for Alzheimer's disease (AD) research [1].

BChE-IN-13, administered at concentrations ranging from 5-100 μM over a 24-hour period, demonstrates minimal toxicity towards SH-SY5Y, PC-12, and HT-22 cells, maintaining over 60% viability even at the highest concentration. Conversely, it significantly affects BV2 cells, with a noteworthy mortality rate that reaches 50% at a concentration of 20 μM. Furthermore, BChE-IN-13 exhibits excellent penetration through the blood-brain barrier, as evidenced by its performance in Parallel Artificial Membrane Permeability Assay (PAMPA) experiments. This dual activity profile highlights its potential for selective application in neurological contexts.

BChE-IN-13, administered through oral gavage at a dosage of 15 mg/kg once daily for 6 days, enhances memory and cognitive functions in mice exhibiting Alzheimer's disease-like symptoms induced by Aβ 1-42 [1]. In this study, ICR mice were intracerebroventricularly injected with oligomerized Aβ 1-42 to model the disorder. The observed improvement in cognitive performance and memory, evidenced by reduced latency, was more significant compared to the effect seen with Donepezil.